Author

P. Chaudhari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Choughule· 1 shared A. Dutt· 1 shared A. Ingle· 1 shared A. Joshi· 1 shared A. K. Dey· 1 shared A. Navalkar· 1 shared B. Dharavath· 1 shared B. K. Mohanty· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Choughule

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Nuclear Location Bias of HCAR1 Drives Cancer Malignancy through Numerous Routes

M. A. M. Nezhady, G. Cagnone, E. Bajon, P. Chaudhari, M. Modaresinejad, P. Hardy, D. Maggiorani, C. Quiniou, J.-S. Joyal, C. Beausejour, S. Chemtob

This study identifies nuclear localization of HCAR1 as a driver of cancer malignancy through multiple mechanisms including nuclear signaling and transcriptomic regulation.

bioRxiv · Jul 25, 2022 · PreprintCell Biology

Induction of intracellular wild-type p53 amyloids leading to cellular transformation and tumor formation in mice

A. Navalkar, S. Pandey, N. Singh, A. K. Dey, S. Saha, K. Patel, B. K. Mohanty, S. Jadhav, P. Chaudhari, T. K. Maiti, S. K. Maji

This study shows that wild-type p53 amyloid formation leads to cellular transformation and tumor formation in mice by enhancing survival, proliferation, and migration while suppressing tumor suppressors.

bioRxiv · Jun 4, 2020 · PreprintCancer Biology

ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in early stage Gallbladder Cancer

P. Iyer, S. V. Shrikhande, M. Ranjan, A. Joshi, R. Prasad, N. Gardi, R. Thorat, S. Salunkhe, B. Dharavath, B. Sahoo, P. Chandrani, H. Kore, B. Mohanty, V. Chaudhari, A. Choughule, , A. Dutt

This study identifies ERBB2 and KRAS mutations in early-stage gallbladder cancer and shows their impact on response to EGFR inhibitors.

bioRxiv · Mar 28, 2018Cancer Biology